Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

McKESSON'S $775 MIL. GENERAL MEDICAL BUY GIVES DRUG WHOLESALER ENTRY INTO MED/SURG, ALTERNATE SITE MARKETS; DEAL INCLUDES ASSUMPTION OF $428 MIL. DEBT

This article was originally published in The Gray Sheet

  • News

Executive Summary

McKesson's $775 mil. acquisition of General Medical gives the nation's largest pharmaceutical wholesaler a medical/surgical distributor with strength in the alternate site market.

You may also be interested in...



McKesson Makes Med/Surg Leadership, Process Changes To Boost Results

McKesson remains committed to its $684 mil. Medical-Surgical Solutions segment, citing untapped potential in the alternate-site health care market

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.

Table

View full table

Tags:
Latest Headlines

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use

UK MHRA Updates Assistive Tech And Borderline Regulations

EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions

See All
UsernamePublicRestriction

Register

MT007499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By